Skip to content

A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis

A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02016482
Enrollment
217
Registered
2013-12-20
Start date
2014-01-31
Completion date
2016-04-30
Last updated
2017-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nail Psoriasis, Plaque Psoriasis

Keywords

Nail Psoriasis, Plaque Psoriasis

Brief summary

This study is being conducted to assess the safety and efficacy of adalimumab in participants with nail psoriasis.

Interventions

BIOLOGICALAdalimumab
OTHERPlacebo

Sponsors

AbbVie
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Subject must have body surface area (BSA) ≥ 10% and a target fingernail Modified Nail Psoriasis Severity Index (mNAPSI) ≥ 8 at Week 0, OR BSA ≥ 5%, a target fingernail mNAPSI ≥ 8 and a total mNAPSI score of ≥ 20 at Week 0. * Subject must have a Nail Psoriasis Physical Functioning Severity score of \> 3, OR a Nail Psoriasis Pain Numeric Rating Scale (NRS) score of \>3. * Subjects must have a Physician's Global Assessment (PGA) of Fingernail Psoriasis and a PGA of Skin Psoriasis of at least moderate. * Subject must have discontinued use of all systemic therapies for the treatment of psoriasis, or systemic therapies known to improve psoriasis for at least 4 weeks prior to Week 0, ustekinumab must have been discontinued at least 12 weeks prior to Week 0. * Target fingernail must have mNAPSI score of ≥ 8. * Adult subjects with clinical diagnosis of chronic plaque psoriasis (with disease duration of at least 6 months).

Exclusion criteria

* Prior adalimumab therapy. * Diagnosis of other active skin diseases or skin infections (bacterial, fungal, or viral) that may interfere with evaluation of skin or fingernail psoriasis. * Recent infection requiring treatment. * Significant medical events or conditions that may put patients at risk for participation, including recent history of drug or alcohol abuse. * Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study. * History of cancer, except successfully treated skin cancer.

Design outcomes

Primary

MeasureTime frameDescription
Percentage of Participants Achieving a Total Fingernail Modified Nail Psoriasis Severity Index (mNAPSI) 75 Response at Week 26Week 26Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. Investigators assessed each nail abnormality for each of a participant's nails by grading 3 features or groups of features (pitting, onycholysis and oil-drop dyschromia, and crumbling) and noting the presence or absence of 4 features (leukonychia, splinter hemorrhages, hyperkeratosis, and red spots in the lunula). The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement. The mNAPSI 75 response is defined as at least 75% reduction from baseline in mNAPSI.
For United States (US) Regulatory Purposes: Percentage of Participants With a Physician's Global Assessment of Fingernails (PGA-F) of Clear or Minimal at Week 26Week 26The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe, was separately assigned for nail bed involvement and nail matrix involvement. A participant's overall global score was the worse of the nail bed and nail matrix score. Data presents the percentage of participants with a PGA-F overall global score that met the definition of clear (0) or minimal (1) with at least a 2-grade improvement relative to Baseline at Week 26.

Secondary

MeasureTime frameDescription
Percent Change From Baseline in Nail Psoriasis Pain Numeric Rating Scale (NRS) at Week 26Baseline, Week 26An NRS was used to capture a participant's self-reporting of her/his worst fingernail pain and average fingernail pain due to fingernail psoriasis. The participant rated the severity of fingernail pain over the past 7 days on a scale from 0 indicating no pain, to 10 indicating severe pain. A negative change from Baseline indicates improvement.
Change From Baseline in Nail Psoriasis Physical Functioning Severity Score at Week 26Baseline, Week 26Participants were asked to rate the impact of their fingernail psoriasis on their ability to perform physical tasks (eg, typing, housework, buttoning a shirt or blouse, picking up coins from a table, tying shoes, yard work, etc.) over the past 7 days on a scale of 0 indicating no impact on ability to perform physical tasks, to 10 indicating severe impact on ability to perform physical tasks. A negative change from Baseline indicates improvement.
Percentage of Participants With at Least 50% Improvement in the Scalp Component of the Brigham Scalp Nail Inverse Palmo-Plantar Psoriasis Index (B-SNIPI) at Week 26Baseline, Week 26The range of possible scores was 0 to 20 for scalp psoriasis, with a score of 0 indicating absence of psoriasis. A decrease in B-SNIPI score indicates improvement. Data presents the percentage of participants achieving 50% improvement in the scalp component of the B-SNIPI among participants with Baseline scalp score of ≥ 6.
Percentage of Participants Achieving Clear or Minimal in Nail Bed Component of the PGA-F at Week 26Week 26The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe, was separately assigned for nail bed involvement and nail matrix involvement. A participant's overall global score was the worse of the nail bed and nail matrix score. Data presents the percentage of participants with a nail bed component of the PGA-F that met definition of clear (0) or minimal (1) among those with a Baseline nail bed component of moderate or worse.
Percentage of Participants Achieving Clear or Minimal in Nail Matrix Component of the PGA-F At Week 26Week 26The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe, was separately assigned for nail bed involvement and nail matrix involvement. A participant's overall global score was the worse of the nail bed and nail matrix score. Data presents the percentage of participants with a nail matrix component of the PGA-F that met definition of clear (0) or minimal (1) among those with a Baseline nail matrix component of moderate or worse.
Percentage of Participants Achieving Target Fingernail mNAPSI Score of 0 at Week 26Week 26The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.
Percentage of Participants Achieving Target Fingernail mNAPSI Score of ≤ 2 at Week 26Week 26The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.
Percentage of Participants Achieving Total Fingernail mNAPSI Score of ≤ 2 at Week 26Week 26Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.
Change From Baseline in Target Fingernail mNAPSI Score at Week 26Baseline, Week 26The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.
Percent Change From Baseline in Target Fingernail mNAPSI Score at Week 26Baseline, Week 26The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.
Change From Baseline in Total Fingernail mNAPSI Score at Week 26Baseline, Week 26Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.
Percent Change From Baseline in Total Fingernail mNAPSI Score at Week 26Baseline, Week 26Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.
Percentage of Participants Achieving Total Fingernail NAPSI Score of 0 at Week 26Week 26Each fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 80, with a score of 0 indicating absence of nail psoriasis and 80 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.
Percentage of Participants Achieving Target Fingernail NAPSI Score of 0 at Week 26Week 26The target fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI. The range of possible scores was 0 to 8, with a score of 0 indicating absence of nail psoriasis and 8 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.
Change From Baseline in Target Fingernail NAPSI Score at Week 26Baseline, Week 26The target fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI. The range of possible scores was 0 to 8, with a score of 0 indicating absence of nail psoriasis and 8 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.
Percent Change From Baseline in Target Fingernail NAPSI Score at Week 26Baseline, Week 26The target fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI. The range of possible scores was 0 to 8, with a score of 0 indicating absence of nail psoriasis and 8 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.
Change From Baseline in Total Fingernail NAPSI Score at Week 26Baseline, Week 26Each fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 80, with a score of 0 indicating absence of nail psoriasis and 80 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.
Change From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 26Baseline, Week 26PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. A decrease in PASI score indicates improvement.
Percent Change From Baseline in PASI Score at Week 26Baseline, Week 26PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. A decrease in PASI score indicates improvement.
Percentage of Participants Achieving PASI 75/50/90/100 Responses at Week 26Week 26PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. PASI-75, 50, 90, and 100 responses are the percentage of participants with a Baseline PASI score ≥ 5 who achieved at least a 75%, 50%, 90%, or 100% reduction (improvement), respectively, from Baseline in PASI score at Week 26. A 100% reduction was considered complete clearance of psoriasis. Data presents the percentage of participants achieving PASI 75/50/90/100 responses at Week 26 among participants with a Baseline PASI score ≥ 5.
Percentage of Participants Achieving Physician's Global Assessment of Skin Psoriasis (PGA-S) Clear or Minimal at Week 26Week 26The PGA-S is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was assessed, with 0 indicating cleared and 5 indicating severe. A decrease in PGA-S score indicates improvement. Data present the percentage of participants achieving a PGA-S of clear (0) or minimal (1) with at least a 2-grade improvement relative to Baseline at Week 26.
Percentage of Participants Achieving PGA-S of Clear at Week 26Week 26The PGA-S is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was assessed, with 0 indicating cleared and 5 indicating severe. A decrease in PGA-S score indicates improvement. Data present the percentage of participants achieving a PGA-S of clear (0) with at least a 2-grade improvement relative to Baseline at Week 26.
Percentage of Participants Achieving 50% Improvement in the Inverse Psoriasis Component of the B-SNIPI at Week 26Week 26The range of possible B-SNIPI scores was 0 to 20 for inverse psoriasis, with a score of 0 indicating absence of psoriasis and a score of 20 indicating most severe psoriasis. A decrease in B-SNIPI score indicates improvement. Data presents the percentage of participants achieving 50% improvement in the inverse component of the B-SNIPI among participants with a Baseline inverse psoriasis score of ≥ 6.
Change From Baseline in Total Body Surface Area (BSA) at Week 26Baseline, Week 26BSA affected by psoriasis was measured by the physician selecting the participant's right or left hand as the measuring device. For purposes of clinical estimation, the total surface of the palm plus 5 digits was to be assumed to be approximately equivalent to 1% BSA. Measurement of the total area of involvement by the physician was aided by imagining if scattered plaques were moved so that they were next to each other and then estimated the total area involved. A decrease in BSA affected by psoriasis indicates improvement.
Percent Change From Baseline in Total BSA at Week 26Baseline, Week 26BSA affected by psoriasis was measured by the physician selecting the participant's right or left hand as the measuring device. For purposes of clinical estimation, the total surface of the palm plus 5 digits was to be assumed to be approximately equivalent to 1% BSA. Measurement of the total area of involvement by the physician was aided by imagining if scattered plaques were moved so that they were next to each other and then estimated the total area involved. A decrease in BSA affected by psoriasis indicates improvement.
Percent Change From Baseline in Nail Psoriasis Pain NRS at Week 26Baseline, Week 26An NRS was used to capture a participant's self-reporting of her/his worst fingernail pain and average fingernail pain due to fingernail psoriasis. The participant rated the severity of fingernail pain over the past 7 days on a scale from 0 indicating no pain, to 10 indicating severe pain. A negative change from Baseline indicates improvement.
Percent Change From Baseline in Nail Psoriasis Physical Functioning Severity Score at Week 26Baseline, Week 26Participants were asked to rate the impact of their fingernail psoriasis on their ability to perform physical tasks (eg, typing, housework, buttoning a shirt or blouse, picking up coins from a table, tying shoes, yard work, etc.) over the past 7 days on a scale of 0 indicating no impact on ability to perform physical tasks, to 10 indicating severe impact on ability to perform physical tasks. A negative change from Baseline indicates improvement.
Change From Baseline in Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life (NAPPA QoL) at Week 26Baseline, Week 26Participants rated specific impacts of fingernail psoriasis on various aspects of their QoL over the past 7 days on a 5-point scale, with 0 indicating not at all, and 4 indicating very impactful. A participant's overall global score was the mean of all items and could range from 0 to 4, with 0 indicating no impact and 4 indicating most impact. A decrease in NAPPA QoL score indicates improvement.
Percent Change From Baseline in Nail Assessment in NAPPA QoL at Week 26Baseline, Week 26Participants rated specific impacts of fingernail psoriasis on various aspects of their QoL over the past 7 days on a 5-point scale, with 0 indicating not at all, and 4 indicating very impactful. A participant's overall global score was the mean of all items and could range from 0 to 4, with 0 indicating no impact and 4 indicating most impact. A decrease in NAPPA QoL score indicates improvement.
Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 26Baseline, Week 26Participants assessed symptoms and impacts of dermatologic diseases on their QoL over the past 7 days, with 0 indicating not at all, and 3 indicating very much. The range of possible DLQI scores was 0 to 30, with a score of 0 indicating no effect at all on a participant's life and a score of 30 indicating extremely large effect on participant's life. A decrease in DLQI score indicates improvement.
Percentage of Participants Achieving DLQI of 0 and 0/1 at Week 26Week 26Participants assessed symptoms and impacts of dermatologic diseases on their QoL over the past 7 days, with 0 indicating not at all, and 3 indicating very much. The range of possible DLQI scores was 0 to 30, with a score of 0 indicating no effect at all on a participant's life and a score of 30 indicating extremely large effect on participant's life. A decrease in DLQI score indicates improvement. Data presents the percentage of participants with a score of 0 (no effect) or 1 (little effect) at Week 26.
Change From Baseline in Work Productivity and Activity Impairment Nail Psoriasis (WPAI:NPSO) at Week 26Baseline, Week 26The WPAI: NPSO assessed impact of fingernail psoriasis on work productivity and non-work activity limitation. Participants were asked during the past 7 days, how many hours did you miss from work because of problems associated with your fingernail psoriasis (absenteeism), during the past seven days, how many hours did you miss from work because of any other reason, such as vacation, holidays, time off to participate in this study (presenteeism), how much did your fingernail psoriasis affect your productivity while you were working (overall work impairment), and much did your fingernail psoriasis affect your ability to do your regular daily activities, other than work at a job (activity impairment). Answers were rated on an 11-point scale, with 0 indicating fingernail psoriasis had no effect on this and 10 indicating fingernail psoriasis completely prevented me from this. A decrease in the WPAI:NPSO score indicates improvement.
Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Health State Assessment at Week 26Baseline, Week 26The EQ-5D-5L descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the subject's current health state. Each dimension comprises 5 levels with corresponding numeric scores, where 1 indicates no problems, and 5 indicates extreme problems. A unique EQ-5D-5L health state is defined by combining the numeric level scores for each of the 5 dimensions and the total score is normalized from -0.594 to 1.000, with higher scores representing a better health state. An increase in the EQ-5D-5L total score indicates improvement.
Percent Change From Baseline in Total Fingernail Nail Psoriasis Severity Index (NAPSI) Score at Week 26Baseline, Week 26Each fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 80, with a score of 0 indicating absence of nail psoriasis and 80 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.
Change From Baseline in Hospital Anxiety Depression Scale (HADS) at Week 26Baseline, Week 26Participants rated their anxiety and depression over the past 7 days at Week 26. The range of possible scores was 0 to 21, with a score of 0 indicating absence of anxiety and depression and 21 indicating the most severe anxiety and depression. A decrease in HADS score indicates improvement.
Percentage of Participants With a New Diagnosis of Psoriatic Arthritis (PsA) During the Studyup to Week 26The percentage of participants with a new diagnosis of PsA (ie, with an adverse event of PsA) during the study, among participants without PsA at Baseline.
Change From Baseline in Nail Psoriasis Quality of Life (Nail PsQoL) Score at Week 26Baseline, Week 26Participants were asked how their fingernail psoriasis impacted their overall quality of life over the past 7 days on an 11-point scale, with 0 indicating no impact, and 10 indicating severe impact. A negative change from Baseline indicates improvement.
Change From Baseline in EQ-5D Visual Analogue Scale (VAS) at Week 26Baseline, Week 26The EQ-5D VAS records the participant's self-rated health status on a vertical graduated scale from 0 to 100, with 0 indicating the worst imaginable health state and 100 indicating the best imaginable health state. An increase in EQ-5D-5L VAS score indicates improvement.
Percentage of Participants Achieving Total Fingernail mNAPSI Score of 0 at Week 26Week 26Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

Participant flow

Participants by arm

ArmCount
Placebo
Period A: Placebo sc eow for 25 weeks. Period B: ADA 80 mg sc at Week 26 followed by ADA 40 mg sc eow from Week 27 through Week 51.
108
Adalimumab EOW
Period A: ADA 40 mg sc eow for 25 weeks starting 1 week after initial loading dose of 80 mg. Period B: Placebo at Week 26 followed by ADA 40 mg sc eow from Week 27 through Week 51.
109
Total217

Withdrawals & dropouts

PeriodReasonFG000FG001
Period AAdverse Event35
Period ALack of Efficacy21
Period ALost to Follow-up33
Period AOther30
Period AProtocol Violation01
Period ARequired Alternative/Prohibited Therapy01
Period AWithdrawal by Subject34
Period BLack of Efficacy64
Period BLost to Follow-up20
Period BOther40
Period BRequired Alternative/Prohibited Therapy02
Period BWithdrawal by Subject11

Baseline characteristics

CharacteristicPlaceboAdalimumab EOWTotal
Age, Continuous46.16 years
STANDARD_DEVIATION 12.134
47.21 years
STANDARD_DEVIATION 11.858
46.69 years
STANDARD_DEVIATION 11.98
Age, Customized
40 to ≤ 64 years
65 participants70 participants135 participants
Age, Customized
< 40 years
34 participants30 participants64 participants
Age, Customized
≥ 65 years
9 participants9 participants18 participants
Sex: Female, Male
Female
21 Participants13 Participants34 Participants
Sex: Female, Male
Male
87 Participants96 Participants183 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —— / —
other
Total, other adverse events
43 / 10845 / 10928 / 9434 / 94
serious
Total, serious adverse events
5 / 1088 / 1093 / 943 / 94

Outcome results

Primary

For United States (US) Regulatory Purposes: Percentage of Participants With a Physician's Global Assessment of Fingernails (PGA-F) of Clear or Minimal at Week 26

The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe, was separately assigned for nail bed involvement and nail matrix involvement. A participant's overall global score was the worse of the nail bed and nail matrix score. Data presents the percentage of participants with a PGA-F overall global score that met the definition of clear (0) or minimal (1) with at least a 2-grade improvement relative to Baseline at Week 26.

Time frame: Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline. Multiple imputation.

ArmMeasureValue (NUMBER)
PlaceboFor United States (US) Regulatory Purposes: Percentage of Participants With a Physician's Global Assessment of Fingernails (PGA-F) of Clear or Minimal at Week 266.9 percentage of participants
Adalimumab EOWFor United States (US) Regulatory Purposes: Percentage of Participants With a Physician's Global Assessment of Fingernails (PGA-F) of Clear or Minimal at Week 2648.9 percentage of participants
Comparison: Ranked sixth secondary endpoint. For US regulatory purposes, this was the primary endpoint.p-value: <0.00195% CI: [30.8, 53.2]Cochran-Mantel-Haenszel
Primary

Percentage of Participants Achieving a Total Fingernail Modified Nail Psoriasis Severity Index (mNAPSI) 75 Response at Week 26

Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. Investigators assessed each nail abnormality for each of a participant's nails by grading 3 features or groups of features (pitting, onycholysis and oil-drop dyschromia, and crumbling) and noting the presence or absence of 4 features (leukonychia, splinter hemorrhages, hyperkeratosis, and red spots in the lunula). The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement. The mNAPSI 75 response is defined as at least 75% reduction from baseline in mNAPSI.

Time frame: Week 26

Population: Intent-to-treat (ITT) Population in Period A: all participants who were randomized at Baseline.

ArmMeasureValue (NUMBER)
PlaceboPercentage of Participants Achieving a Total Fingernail Modified Nail Psoriasis Severity Index (mNAPSI) 75 Response at Week 263.4 percentage of participants
Adalimumab EOWPercentage of Participants Achieving a Total Fingernail Modified Nail Psoriasis Severity Index (mNAPSI) 75 Response at Week 2646.6 percentage of participants
Comparison: For US regulatory purposes, ranked first secondary endpoint.p-value: <0.00195% CI: [32.8, 53.6]Cochran-Mantel-Haenszel
Secondary

Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 26

Participants assessed symptoms and impacts of dermatologic diseases on their QoL over the past 7 days, with 0 indicating not at all, and 3 indicating very much. The range of possible DLQI scores was 0 to 30, with a score of 0 indicating no effect at all on a participant's life and a score of 30 indicating extremely large effect on participant's life. A decrease in DLQI score indicates improvement.

Time frame: Baseline, Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline and had an assessment. Multiple imputation.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboChange From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 26-1.9 units on a scaleStandard Error 0.6
Adalimumab EOWChange From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 26-8.0 units on a scaleStandard Error 0.6
p-value: <0.00195% CI: [-7.8, -4.5]ANCOVA
Secondary

Change From Baseline in EQ-5D Visual Analogue Scale (VAS) at Week 26

The EQ-5D VAS records the participant's self-rated health status on a vertical graduated scale from 0 to 100, with 0 indicating the worst imaginable health state and 100 indicating the best imaginable health state. An increase in EQ-5D-5L VAS score indicates improvement.

Time frame: Baseline, Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline and had an assessment. Multiple imputation.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboChange From Baseline in EQ-5D Visual Analogue Scale (VAS) at Week 26-0.1 units on a scaleStandard Error 1.53
Adalimumab EOWChange From Baseline in EQ-5D Visual Analogue Scale (VAS) at Week 265.5 units on a scaleStandard Error 1.53
p-value: 0.01295% CI: [1.2, 9.8]ANCOVA
Secondary

Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Health State Assessment at Week 26

The EQ-5D-5L descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the subject's current health state. Each dimension comprises 5 levels with corresponding numeric scores, where 1 indicates no problems, and 5 indicates extreme problems. A unique EQ-5D-5L health state is defined by combining the numeric level scores for each of the 5 dimensions and the total score is normalized from -0.594 to 1.000, with higher scores representing a better health state. An increase in the EQ-5D-5L total score indicates improvement.

Time frame: Baseline, Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline and had an assessment. Multiple imputation.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboChange From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Health State Assessment at Week 260.0 units on a scaleStandard Error 0.01
Adalimumab EOWChange From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Health State Assessment at Week 260.1 units on a scaleStandard Error 0.01
p-value: <0.00195% CI: [0.1, 0.2]ANCOVA
Secondary

Change From Baseline in Hospital Anxiety Depression Scale (HADS) at Week 26

Participants rated their anxiety and depression over the past 7 days at Week 26. The range of possible scores was 0 to 21, with a score of 0 indicating absence of anxiety and depression and 21 indicating the most severe anxiety and depression. A decrease in HADS score indicates improvement.

Time frame: Baseline, Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline; n=number of participants with a given assessment. Multiple imputation.

ArmMeasureGroupValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboChange From Baseline in Hospital Anxiety Depression Scale (HADS) at Week 26HADS anxiety score; n=106, 109-0.1 units on a scaleStandard Error 0.33
PlaceboChange From Baseline in Hospital Anxiety Depression Scale (HADS) at Week 26HADS depression score; n=106, 1080.0 units on a scaleStandard Error 0.33
Adalimumab EOWChange From Baseline in Hospital Anxiety Depression Scale (HADS) at Week 26HADS anxiety score; n=106, 109-1.1 units on a scaleStandard Error 0.33
Adalimumab EOWChange From Baseline in Hospital Anxiety Depression Scale (HADS) at Week 26HADS depression score; n=106, 108-1.4 units on a scaleStandard Error 0.32
Comparison: HADS anxiety scorep-value: 0.02595% CI: [-2, -0.1]ANCOVA
Comparison: HADS depression scorep-value: 0.00595% CI: [-2.3, -0.4]ANCOVA
Secondary

Change From Baseline in Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life (NAPPA QoL) at Week 26

Participants rated specific impacts of fingernail psoriasis on various aspects of their QoL over the past 7 days on a 5-point scale, with 0 indicating not at all, and 4 indicating very impactful. A participant's overall global score was the mean of all items and could range from 0 to 4, with 0 indicating no impact and 4 indicating most impact. A decrease in NAPPA QoL score indicates improvement.

Time frame: Baseline, Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline. Multiple imputation.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboChange From Baseline in Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life (NAPPA QoL) at Week 26-0.4 units on a scaleStandard Error 0.07
Adalimumab EOWChange From Baseline in Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life (NAPPA QoL) at Week 26-1.3 units on a scaleStandard Error 0.07
p-value: <0.00195% CI: [-1.1, -0.7]ANCOVA
Secondary

Change From Baseline in Nail Psoriasis Physical Functioning Severity Score at Week 26

Participants were asked to rate the impact of their fingernail psoriasis on their ability to perform physical tasks (eg, typing, housework, buttoning a shirt or blouse, picking up coins from a table, tying shoes, yard work, etc.) over the past 7 days on a scale of 0 indicating no impact on ability to perform physical tasks, to 10 indicating severe impact on ability to perform physical tasks. A negative change from Baseline indicates improvement.

Time frame: Baseline, Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboChange From Baseline in Nail Psoriasis Physical Functioning Severity Score at Week 26-0.8 units on a scaleStandard Error 0.24
Adalimumab EOWChange From Baseline in Nail Psoriasis Physical Functioning Severity Score at Week 26-3.7 units on a scaleStandard Error 0.25
Comparison: Ranked fourth secondary endpoint. For US regulatory purposes, ranked fifth secondary endpoint.p-value: <0.00195% CI: [-3.6, -2.2]ANCOVA
Secondary

Change From Baseline in Nail Psoriasis Quality of Life (Nail PsQoL) Score at Week 26

Participants were asked how their fingernail psoriasis impacted their overall quality of life over the past 7 days on an 11-point scale, with 0 indicating no impact, and 10 indicating severe impact. A negative change from Baseline indicates improvement.

Time frame: Baseline, Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline and had an assessment. Multiple imputation.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboChange From Baseline in Nail Psoriasis Quality of Life (Nail PsQoL) Score at Week 26-0.6 units on a scaleStandard Error 0.23
Adalimumab EOWChange From Baseline in Nail Psoriasis Quality of Life (Nail PsQoL) Score at Week 26-3.3 units on a scaleStandard Error 0.23
p-value: <0.00195% CI: [-3.4, -2.1]ANCOVA
Secondary

Change From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 26

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. A decrease in PASI score indicates improvement.

Time frame: Baseline, Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline. Multiple imputation.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboChange From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 26-0.9 units on a scaleStandard Error 0.7
Adalimumab EOWChange From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 26-9.0 units on a scaleStandard Error 0.7
p-value: <0.00195% CI: [-10, -6.1]ANCOVA
Secondary

Change From Baseline in Target Fingernail mNAPSI Score at Week 26

The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

Time frame: Baseline, Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline. Multiple imputation.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboChange From Baseline in Target Fingernail mNAPSI Score at Week 26-2.1 units on a scaleStandard Error 0.27
Adalimumab EOWChange From Baseline in Target Fingernail mNAPSI Score at Week 26-5.7 units on a scaleStandard Error 0.27
p-value: <0.00195% CI: [-4.3, -2.8]ANCOVA
Secondary

Change From Baseline in Target Fingernail NAPSI Score at Week 26

The target fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI. The range of possible scores was 0 to 8, with a score of 0 indicating absence of nail psoriasis and 8 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.

Time frame: Baseline, Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline. Multiple imputation.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboChange From Baseline in Target Fingernail NAPSI Score at Week 26-1.1 units on a scaleStandard Error 0.21
Adalimumab EOWChange From Baseline in Target Fingernail NAPSI Score at Week 26-3.6 units on a scaleStandard Error 0.21
p-value: <0.00195% CI: [-3.1, -1.9]ANCOVA
Secondary

Change From Baseline in Total Body Surface Area (BSA) at Week 26

BSA affected by psoriasis was measured by the physician selecting the participant's right or left hand as the measuring device. For purposes of clinical estimation, the total surface of the palm plus 5 digits was to be assumed to be approximately equivalent to 1% BSA. Measurement of the total area of involvement by the physician was aided by imagining if scattered plaques were moved so that they were next to each other and then estimated the total area involved. A decrease in BSA affected by psoriasis indicates improvement.

Time frame: Baseline, Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline. Multiple imputation.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboChange From Baseline in Total Body Surface Area (BSA) at Week 260.4 percentage of affected BSAStandard Error 1
Adalimumab EOWChange From Baseline in Total Body Surface Area (BSA) at Week 26-10.7 percentage of affected BSAStandard Error 1
p-value: <0.00195% CI: [-13.9, -8.4]ANCOVA
Secondary

Change From Baseline in Total Fingernail mNAPSI Score at Week 26

Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

Time frame: Baseline, Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline. Multiple imputation.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboChange From Baseline in Total Fingernail mNAPSI Score at Week 26-7.5 units on a scaleStandard Error 1.78
Adalimumab EOWChange From Baseline in Total Fingernail mNAPSI Score at Week 26-36.1 units on a scaleStandard Error 1.8
p-value: <0.00195% CI: [-33.5, -23.7]ANCOVA
Secondary

Change From Baseline in Total Fingernail NAPSI Score at Week 26

Each fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 80, with a score of 0 indicating absence of nail psoriasis and 80 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.

Time frame: Baseline, Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline. Multiple imputation.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboChange From Baseline in Total Fingernail NAPSI Score at Week 26-6.7 units on a scaleStandard Error 1.51
Adalimumab EOWChange From Baseline in Total Fingernail NAPSI Score at Week 26-26.2 units on a scaleStandard Error 1.47
p-value: <0.00195% CI: [-23.6, -15.3]ANCOVA
Secondary

Change From Baseline in Work Productivity and Activity Impairment Nail Psoriasis (WPAI:NPSO) at Week 26

The WPAI: NPSO assessed impact of fingernail psoriasis on work productivity and non-work activity limitation. Participants were asked during the past 7 days, how many hours did you miss from work because of problems associated with your fingernail psoriasis (absenteeism), during the past seven days, how many hours did you miss from work because of any other reason, such as vacation, holidays, time off to participate in this study (presenteeism), how much did your fingernail psoriasis affect your productivity while you were working (overall work impairment), and much did your fingernail psoriasis affect your ability to do your regular daily activities, other than work at a job (activity impairment). Answers were rated on an 11-point scale, with 0 indicating fingernail psoriasis had no effect on this and 10 indicating fingernail psoriasis completely prevented me from this. A decrease in the WPAI:NPSO score indicates improvement.

Time frame: Baseline, Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline; n=number of participants with given assessment. Multiple imputation.

ArmMeasureGroupValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboChange From Baseline in Work Productivity and Activity Impairment Nail Psoriasis (WPAI:NPSO) at Week 26Presenteeism; n=70, 77-3.4 units on a scaleStandard Error 2.08
PlaceboChange From Baseline in Work Productivity and Activity Impairment Nail Psoriasis (WPAI:NPSO) at Week 26Absenteeism; n=65, 74-1.0 units on a scaleStandard Error 0.73
PlaceboChange From Baseline in Work Productivity and Activity Impairment Nail Psoriasis (WPAI:NPSO) at Week 26Overall Work impairment; n=65, 74-6.2 units on a scaleStandard Error 2.2
PlaceboChange From Baseline in Work Productivity and Activity Impairment Nail Psoriasis (WPAI:NPSO) at Week 26Activity impairment; n=106, 108-1.8 units on a scaleStandard Error 2.09
Adalimumab EOWChange From Baseline in Work Productivity and Activity Impairment Nail Psoriasis (WPAI:NPSO) at Week 26Presenteeism; n=70, 77-20.7 units on a scaleStandard Error 2.06
Adalimumab EOWChange From Baseline in Work Productivity and Activity Impairment Nail Psoriasis (WPAI:NPSO) at Week 26Activity impairment; n=106, 108-23.1 units on a scaleStandard Error 2.18
Adalimumab EOWChange From Baseline in Work Productivity and Activity Impairment Nail Psoriasis (WPAI:NPSO) at Week 26Overall Work impairment; n=65, 74-21.3 units on a scaleStandard Error 2.05
Adalimumab EOWChange From Baseline in Work Productivity and Activity Impairment Nail Psoriasis (WPAI:NPSO) at Week 26Absenteeism; n=65, 74-0.3 units on a scaleStandard Error 0.65
Comparison: Absenteeismp-value: 0.41695% CI: [-1, 2.5]ANCOVA
Comparison: Presenteeismp-value: <0.00195% CI: [-22.9, -11.6]ANCOVA
Comparison: Overall work impairmentp-value: <0.00195% CI: [-21, -9.3]ANCOVA
Comparison: Activity impairmentp-value: <0.00195% CI: [-27.3, -15.4]ANCOVA
Secondary

Percentage of Participants Achieving 50% Improvement in the Inverse Psoriasis Component of the B-SNIPI at Week 26

The range of possible B-SNIPI scores was 0 to 20 for inverse psoriasis, with a score of 0 indicating absence of psoriasis and a score of 20 indicating most severe psoriasis. A decrease in B-SNIPI score indicates improvement. Data presents the percentage of participants achieving 50% improvement in the inverse component of the B-SNIPI among participants with a Baseline inverse psoriasis score of ≥ 6.

Time frame: Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline and had Baseline inverse psoriasis score ≥ 6. Inverse psoriasis was assessed for participants enrolled under Protocol Amendment 1 in the US and Puerto Rico only. Multiple imputation.

ArmMeasureValue (NUMBER)
PlaceboPercentage of Participants Achieving 50% Improvement in the Inverse Psoriasis Component of the B-SNIPI at Week 260.5 percentage of participants
Adalimumab EOWPercentage of Participants Achieving 50% Improvement in the Inverse Psoriasis Component of the B-SNIPI at Week 2690.8 percentage of participants
p-value: <0.00195% CI: [72.5, 108.3]Cochran-Mantel-Haenszel
Secondary

Percentage of Participants Achieving Clear or Minimal in Nail Bed Component of the PGA-F at Week 26

The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe, was separately assigned for nail bed involvement and nail matrix involvement. A participant's overall global score was the worse of the nail bed and nail matrix score. Data presents the percentage of participants with a nail bed component of the PGA-F that met definition of clear (0) or minimal (1) among those with a Baseline nail bed component of moderate or worse.

Time frame: Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline and had a Baseline nail bed component of moderate or worse. Multiple imputation.

ArmMeasureValue (NUMBER)
PlaceboPercentage of Participants Achieving Clear or Minimal in Nail Bed Component of the PGA-F at Week 268.2 percentage of participants
Adalimumab EOWPercentage of Participants Achieving Clear or Minimal in Nail Bed Component of the PGA-F at Week 2651.4 percentage of participants
p-value: <0.00195% CI: [31.3, 55.2]Cochran-Mantel-Haenszel
Secondary

Percentage of Participants Achieving Clear or Minimal in Nail Matrix Component of the PGA-F At Week 26

The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe, was separately assigned for nail bed involvement and nail matrix involvement. A participant's overall global score was the worse of the nail bed and nail matrix score. Data presents the percentage of participants with a nail matrix component of the PGA-F that met definition of clear (0) or minimal (1) among those with a Baseline nail matrix component of moderate or worse.

Time frame: Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline and had a Baseline nail matrix component of moderate or worse. Multiple imputations.

ArmMeasureValue (NUMBER)
PlaceboPercentage of Participants Achieving Clear or Minimal in Nail Matrix Component of the PGA-F At Week 268.5 percentage of participants
Adalimumab EOWPercentage of Participants Achieving Clear or Minimal in Nail Matrix Component of the PGA-F At Week 2653.3 percentage of participants
p-value: <0.00195% CI: [33.2, 56.5]Cochran-Mantel-Haenszel
Secondary

Percentage of Participants Achieving DLQI of 0 and 0/1 at Week 26

Participants assessed symptoms and impacts of dermatologic diseases on their QoL over the past 7 days, with 0 indicating not at all, and 3 indicating very much. The range of possible DLQI scores was 0 to 30, with a score of 0 indicating no effect at all on a participant's life and a score of 30 indicating extremely large effect on participant's life. A decrease in DLQI score indicates improvement. Data presents the percentage of participants with a score of 0 (no effect) or 1 (little effect) at Week 26.

Time frame: Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline and had an assessment. Multiple imputation.

ArmMeasureGroupValue (NUMBER)
PlaceboPercentage of Participants Achieving DLQI of 0 and 0/1 at Week 26DLQI = 02.5 percentage of participants
PlaceboPercentage of Participants Achieving DLQI of 0 and 0/1 at Week 26DLQI = 0/13.7 percentage of participants
Adalimumab EOWPercentage of Participants Achieving DLQI of 0 and 0/1 at Week 26DLQI = 018.2 percentage of participants
Adalimumab EOWPercentage of Participants Achieving DLQI of 0 and 0/1 at Week 26DLQI = 0/130.8 percentage of participants
Comparison: DLQI = 0p-value: <0.00195% CI: [7.1, 24.3]Cochran-Mantel-Haenszel
Comparison: DLQI = 0/1p-value: <0.00195% CI: [16.7, 37.4]Cochran-Mantel-Haenszel
Secondary

Percentage of Participants Achieving PASI 75/50/90/100 Responses at Week 26

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. PASI-75, 50, 90, and 100 responses are the percentage of participants with a Baseline PASI score ≥ 5 who achieved at least a 75%, 50%, 90%, or 100% reduction (improvement), respectively, from Baseline in PASI score at Week 26. A 100% reduction was considered complete clearance of psoriasis. Data presents the percentage of participants achieving PASI 75/50/90/100 responses at Week 26 among participants with a Baseline PASI score ≥ 5.

Time frame: Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline and had a Baseline PASI score ≥ 5. Multiple imputation.

ArmMeasureGroupValue (NUMBER)
PlaceboPercentage of Participants Achieving PASI 75/50/90/100 Responses at Week 26PASI 5025.3 percentage of participants
PlaceboPercentage of Participants Achieving PASI 75/50/90/100 Responses at Week 26PASI 907.1 percentage of participants
PlaceboPercentage of Participants Achieving PASI 75/50/90/100 Responses at Week 26PASI 1002.9 percentage of participants
PlaceboPercentage of Participants Achieving PASI 75/50/90/100 Responses at Week 26PASI 7513.8 percentage of participants
Adalimumab EOWPercentage of Participants Achieving PASI 75/50/90/100 Responses at Week 26PASI 10029.3 percentage of participants
Adalimumab EOWPercentage of Participants Achieving PASI 75/50/90/100 Responses at Week 26PASI 9048.0 percentage of participants
Adalimumab EOWPercentage of Participants Achieving PASI 75/50/90/100 Responses at Week 26PASI 5077.8 percentage of participants
Adalimumab EOWPercentage of Participants Achieving PASI 75/50/90/100 Responses at Week 26PASI 7564.8 percentage of participants
Comparison: PASI 75p-value: <0.00195% CI: [38.6, 63.5]Cochran-Mantel-Haenszel
Comparison: PASI 50p-value: <0.00195% CI: [39.9, 65]Cochran-Mantel-Haenszel
Comparison: PASI 90p-value: <0.00195% CI: [29, 52.9]Cochran-Mantel-Haenszel
Comparison: PASI 100p-value: <0.00195% CI: [15.8, 36.9]Cochran-Mantel-Haenszel
Secondary

Percentage of Participants Achieving PGA-S of Clear at Week 26

The PGA-S is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was assessed, with 0 indicating cleared and 5 indicating severe. A decrease in PGA-S score indicates improvement. Data present the percentage of participants achieving a PGA-S of clear (0) with at least a 2-grade improvement relative to Baseline at Week 26.

Time frame: Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline. Multiple imputation.

ArmMeasureValue (NUMBER)
PlaceboPercentage of Participants Achieving PGA-S of Clear at Week 264.0 percentage of participants
Adalimumab EOWPercentage of Participants Achieving PGA-S of Clear at Week 2628.8 percentage of participants
p-value: <0.00195% CI: [15.3, 34.3]Cochran-Mantel-Haenszel
Secondary

Percentage of Participants Achieving Physician's Global Assessment of Skin Psoriasis (PGA-S) Clear or Minimal at Week 26

The PGA-S is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was assessed, with 0 indicating cleared and 5 indicating severe. A decrease in PGA-S score indicates improvement. Data present the percentage of participants achieving a PGA-S of clear (0) or minimal (1) with at least a 2-grade improvement relative to Baseline at Week 26.

Time frame: Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline. Multiple imputation.

ArmMeasureValue (NUMBER)
PlaceboPercentage of Participants Achieving Physician's Global Assessment of Skin Psoriasis (PGA-S) Clear or Minimal at Week 2611.2 percentage of participants
Adalimumab EOWPercentage of Participants Achieving Physician's Global Assessment of Skin Psoriasis (PGA-S) Clear or Minimal at Week 2663.4 percentage of participants
p-value: <0.00195% CI: [40.8, 63.7]Cochran-Mantel-Haenszel
Secondary

Percentage of Participants Achieving Target Fingernail mNAPSI Score of 0 at Week 26

The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

Time frame: Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline. Multiple imputation.

ArmMeasureValue (NUMBER)
PlaceboPercentage of Participants Achieving Target Fingernail mNAPSI Score of 0 at Week 261.3 percentage of participants
Adalimumab EOWPercentage of Participants Achieving Target Fingernail mNAPSI Score of 0 at Week 2619.9 percentage of participants
p-value: <0.00195% CI: [10.6, 26.6]Cochran-Mantel-Haenszel
Secondary

Percentage of Participants Achieving Target Fingernail mNAPSI Score of ≤ 2 at Week 26

The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

Time frame: Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline. Multiple imputation.

ArmMeasureValue (NUMBER)
PlaceboPercentage of Participants Achieving Target Fingernail mNAPSI Score of ≤ 2 at Week 267.3 percentage of participants
Adalimumab EOWPercentage of Participants Achieving Target Fingernail mNAPSI Score of ≤ 2 at Week 2643.3 percentage of participants
p-value: <0.00195% CI: [25, 46.9]Cochran-Mantel-Haenszel
Secondary

Percentage of Participants Achieving Target Fingernail NAPSI Score of 0 at Week 26

The target fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI. The range of possible scores was 0 to 8, with a score of 0 indicating absence of nail psoriasis and 8 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.

Time frame: Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline. Multiple imputation.

ArmMeasureValue (NUMBER)
PlaceboPercentage of Participants Achieving Target Fingernail NAPSI Score of 0 at Week 262.4 percentage of participants
Adalimumab EOWPercentage of Participants Achieving Target Fingernail NAPSI Score of 0 at Week 2620.8 percentage of participants
p-value: <0.00195% CI: [10.1, 26.8]Cochran-Mantel-Haenszel
Secondary

Percentage of Participants Achieving Total Fingernail mNAPSI Score of 0 at Week 26

Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

Time frame: Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline. Multiple imputation.

ArmMeasureValue (NUMBER)
PlaceboPercentage of Participants Achieving Total Fingernail mNAPSI Score of 0 at Week 260.0 percentage of participants
Adalimumab EOWPercentage of Participants Achieving Total Fingernail mNAPSI Score of 0 at Week 266.6 percentage of participants
Comparison: Ranked second secondary endpoint. For US regulatory purposes, ranked third secondary endpoint.p-value: 0.00895% CI: [1.8, 11.3]Cochran-Mantel-Haenszel
Secondary

Percentage of Participants Achieving Total Fingernail mNAPSI Score of ≤ 2 at Week 26

Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

Time frame: Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline. Multiple imputation.

ArmMeasureValue (NUMBER)
PlaceboPercentage of Participants Achieving Total Fingernail mNAPSI Score of ≤ 2 at Week 260.2 percentage of participants
Adalimumab EOWPercentage of Participants Achieving Total Fingernail mNAPSI Score of ≤ 2 at Week 2613.4 percentage of participants
p-value: <0.00195% CI: [6.5, 20]Cochran-Mantel-Haenszel
Secondary

Percentage of Participants Achieving Total Fingernail NAPSI Score of 0 at Week 26

Each fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 80, with a score of 0 indicating absence of nail psoriasis and 80 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.

Time frame: Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline. Multiple imputation.

ArmMeasureValue (NUMBER)
PlaceboPercentage of Participants Achieving Total Fingernail NAPSI Score of 0 at Week 260.0 percentage of participants
Adalimumab EOWPercentage of Participants Achieving Total Fingernail NAPSI Score of 0 at Week 267.5 percentage of participants
p-value: 0.00495% CI: [2.4, 12.4]Cochran-Mantel-Haenszel
Secondary

Percentage of Participants With a New Diagnosis of Psoriatic Arthritis (PsA) During the Study

The percentage of participants with a new diagnosis of PsA (ie, with an adverse event of PsA) during the study, among participants without PsA at Baseline.

Time frame: up to Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline and did not have PsA at Baseline. Observed cases.

ArmMeasureValue (NUMBER)
PlaceboPercentage of Participants With a New Diagnosis of Psoriatic Arthritis (PsA) During the Study0 percentage of participants
Adalimumab EOWPercentage of Participants With a New Diagnosis of Psoriatic Arthritis (PsA) During the Study2 percentage of participants
p-value: 0.16495% CI: [-0.9, 6]Chi-squared
Secondary

Percentage of Participants With at Least 50% Improvement in the Scalp Component of the Brigham Scalp Nail Inverse Palmo-Plantar Psoriasis Index (B-SNIPI) at Week 26

The range of possible scores was 0 to 20 for scalp psoriasis, with a score of 0 indicating absence of psoriasis. A decrease in B-SNIPI score indicates improvement. Data presents the percentage of participants achieving 50% improvement in the scalp component of the B-SNIPI among participants with Baseline scalp score of ≥ 6.

Time frame: Baseline, Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline. Scalp psoriasis was assessed by B-SNIPI at Week 26 for participants enrolled under Protocol Amendment 1 in the US and Puerto Rico only. Multiple imputation.

ArmMeasureValue (NUMBER)
PlaceboPercentage of Participants With at Least 50% Improvement in the Scalp Component of the Brigham Scalp Nail Inverse Palmo-Plantar Psoriasis Index (B-SNIPI) at Week 260.4 percentage of participants
Adalimumab EOWPercentage of Participants With at Least 50% Improvement in the Scalp Component of the Brigham Scalp Nail Inverse Palmo-Plantar Psoriasis Index (B-SNIPI) at Week 2658.3 percentage of participants
Comparison: Ranked fifth secondary endpoint. For US regulatory purposes, ranked sixth secondary endpoint.p-value: 0.00295% CI: [33.8, 82]Cochran-Mantel-Haenszel
Secondary

Percent Change From Baseline in Nail Assessment in NAPPA QoL at Week 26

Participants rated specific impacts of fingernail psoriasis on various aspects of their QoL over the past 7 days on a 5-point scale, with 0 indicating not at all, and 4 indicating very impactful. A participant's overall global score was the mean of all items and could range from 0 to 4, with 0 indicating no impact and 4 indicating most impact. A decrease in NAPPA QoL score indicates improvement.

Time frame: Baseline, Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline. Multiple imputation.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboPercent Change From Baseline in Nail Assessment in NAPPA QoL at Week 26-11.7 percent changeStandard Error 2.24
Adalimumab EOWPercent Change From Baseline in Nail Assessment in NAPPA QoL at Week 26-39.5 percent changeStandard Error 2.23
p-value: <0.00195% CI: [-33.9, -21.6]ANCOVA
Secondary

Percent Change From Baseline in Nail Psoriasis Pain NRS at Week 26

An NRS was used to capture a participant's self-reporting of her/his worst fingernail pain and average fingernail pain due to fingernail psoriasis. The participant rated the severity of fingernail pain over the past 7 days on a scale from 0 indicating no pain, to 10 indicating severe pain. A negative change from Baseline indicates improvement.

Time frame: Baseline, Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline and had an assessment (participants with an observed baseline value \>0). Multiple imputation.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboPercent Change From Baseline in Nail Psoriasis Pain NRS at Week 26-18.0 percent changeStandard Error 4.8
Adalimumab EOWPercent Change From Baseline in Nail Psoriasis Pain NRS at Week 26-68.9 percent changeStandard Error 4.7
p-value: <0.00195% CI: [-64, -37.8]ANCOVA
Secondary

Percent Change From Baseline in Nail Psoriasis Pain Numeric Rating Scale (NRS) at Week 26

An NRS was used to capture a participant's self-reporting of her/his worst fingernail pain and average fingernail pain due to fingernail psoriasis. The participant rated the severity of fingernail pain over the past 7 days on a scale from 0 indicating no pain, to 10 indicating severe pain. A negative change from Baseline indicates improvement.

Time frame: Baseline, Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboPercent Change From Baseline in Nail Psoriasis Pain Numeric Rating Scale (NRS) at Week 26-1.1 percent changeStandard Error 0.24
Adalimumab EOWPercent Change From Baseline in Nail Psoriasis Pain Numeric Rating Scale (NRS) at Week 26-3.7 percent changeStandard Error 0.23
Comparison: Ranked third secondary endpoint. For US regulatory purposes, ranked fourth secondary endpoint.p-value: <0.00195% CI: [-3.3, -2]ANCOVA
Secondary

Percent Change From Baseline in Nail Psoriasis Physical Functioning Severity Score at Week 26

Participants were asked to rate the impact of their fingernail psoriasis on their ability to perform physical tasks (eg, typing, housework, buttoning a shirt or blouse, picking up coins from a table, tying shoes, yard work, etc.) over the past 7 days on a scale of 0 indicating no impact on ability to perform physical tasks, to 10 indicating severe impact on ability to perform physical tasks. A negative change from Baseline indicates improvement.

Time frame: Baseline, Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline and had an assessment (participants with an observed baseline value \>0). Multiple imputation.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboPercent Change From Baseline in Nail Psoriasis Physical Functioning Severity Score at Week 26-9.9 percent changeStandard Error 5.51
Adalimumab EOWPercent Change From Baseline in Nail Psoriasis Physical Functioning Severity Score at Week 26-67.6 percent changeStandard Error 5.63
p-value: <0.00195% CI: [-73.1, -42.4]ANCOVA
Secondary

Percent Change From Baseline in PASI Score at Week 26

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. A decrease in PASI score indicates improvement.

Time frame: Baseline, Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline. Multiple imputation.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboPercent Change From Baseline in PASI Score at Week 262.4 percent changeStandard Error 5.77
Adalimumab EOWPercent Change From Baseline in PASI Score at Week 26-68.7 percent changeStandard Error 5.7
p-value: <0.00195% CI: [-87.3, -55]ANCOVA
Secondary

Percent Change From Baseline in Target Fingernail mNAPSI Score at Week 26

The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

Time frame: Baseline, Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline. Multiple imputation.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboPercent Change From Baseline in Target Fingernail mNAPSI Score at Week 26-23.0 percent changeStandard Error 2.92
Adalimumab EOWPercent Change From Baseline in Target Fingernail mNAPSI Score at Week 26-61.9 percent changeStandard Error 2.91
p-value: <0.00195% CI: [-46.9, -30.8]ANCOVA
Secondary

Percent Change From Baseline in Target Fingernail NAPSI Score at Week 26

The target fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI. The range of possible scores was 0 to 8, with a score of 0 indicating absence of nail psoriasis and 8 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.

Time frame: Baseline, Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline. Multiple imputation.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboPercent Change From Baseline in Target Fingernail NAPSI Score at Week 26-14.4 percent changeStandard Error 3.5
Adalimumab EOWPercent Change From Baseline in Target Fingernail NAPSI Score at Week 26-54.6 percent changeStandard Error 3.47
p-value: <0.00195% CI: [-50, -30.4]ANCOVA
Secondary

Percent Change From Baseline in Total BSA at Week 26

BSA affected by psoriasis was measured by the physician selecting the participant's right or left hand as the measuring device. For purposes of clinical estimation, the total surface of the palm plus 5 digits was to be assumed to be approximately equivalent to 1% BSA. Measurement of the total area of involvement by the physician was aided by imagining if scattered plaques were moved so that they were next to each other and then estimated the total area involved. A decrease in BSA affected by psoriasis indicates improvement.

Time frame: Baseline, Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline. Multiple imputation.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboPercent Change From Baseline in Total BSA at Week 2612.8 percent changeStandard Error 6.08
Adalimumab EOWPercent Change From Baseline in Total BSA at Week 26-67.8 percent changeStandard Error 6.01
p-value: <0.00195% CI: [-97.9, -63.3]ANCOVA
Secondary

Percent Change From Baseline in Total Fingernail mNAPSI Score at Week 26

Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

Time frame: Baseline, Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline. Multiple imputation.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboPercent Change From Baseline in Total Fingernail mNAPSI Score at Week 26-13.2 percent changeStandard Error 3.06
Adalimumab EOWPercent Change From Baseline in Total Fingernail mNAPSI Score at Week 26-63.3 percent changeStandard Error 3.02
p-value: <0.00195% CI: [-58.3, -41.9]ANCOVA
Secondary

Percent Change From Baseline in Total Fingernail Nail Psoriasis Severity Index (NAPSI) Score at Week 26

Each fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 80, with a score of 0 indicating absence of nail psoriasis and 80 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.

Time frame: Baseline, Week 26

Population: ITT Population in Period A: all participants who were randomized at Baseline.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboPercent Change From Baseline in Total Fingernail Nail Psoriasis Severity Index (NAPSI) Score at Week 26-11.5 percent changeStandard Error 3.19
Adalimumab EOWPercent Change From Baseline in Total Fingernail Nail Psoriasis Severity Index (NAPSI) Score at Week 26-56.2 percent changeStandard Error 3.12
Comparison: Ranked first secondary endpoint. For US regulatory purposes, ranked second secondary endpoint.p-value: <0.00195% CI: [-53.5, -36]ANCOVA

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026